Skip to main content
Triangle logo TriangleGet started

Cabozantinib (NCT01639508)

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity: a one-minute explainerNCT016395081 min

Cabozantinib trial for Non-Small Cell Lung Cancer (NCT01639508). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with metastatic or unresectable non-small-cell lung cancer with RET, ROS1 or NTRK fusions, or qualifying MET or AXL changes. One RET group requires progression after a selective RET inhibitor. Previous cabozantinib is excluded.

The idea: cabozantinib blocks signaling involved in cancer growth and blood-vessel formation. Patients start 60 milligrams orally daily, continuously in 28-day cycles, with reductions for toxicity. Researchers assess response and toxicity. Treatment continues until progression, unacceptable toxicity or withdrawal.

This phase 2 study plans 86 patients. Alexander Drilon leads MSK’s seven recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.